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Abstract
Background: Adherence to prescribing guidelines varies between primary health care units. The aim of the
present study was to investigate correlations between characteristics of primary health care units and adherence to
prescribing objectives for rational drug use with focus on drug information from the pharmaceutical industry.
Methods: A cross-sectional study was performed in all 25 primary health care units in Göteborg, Sweden. A
questionnaire on characteristics of practice settings [(i) size of unit, (ii) profession of head, (iii) use of temporary
physicians, (iv) drug information from the pharmaceutical industry, (v) producer-independent drug information, and
(vi) education on prescribing for newly employed physicians] was sent to the heads of the units. A national sales
register for prescribed drugs (Xplain) was used for evaluation of adherence to the six regional prescribing
objectives concerning proton pump inhibitors (PPIs), angiotensin converting enzyme inhibitors (ACEIs), statins and
antidepressants.
Results: Twenty-two out of 25 primary health care units responded to the questionnaire (response rate 88%). A
physician as head and presence of producer-independent drug information was positively correlated with
adherence to the prescribing objectives (median number of prescribing objectives adhered to (25
th -7 5
th
percentile): 2.5 (1-3.25) vs 1 (0-2), P = 0.013; 2 (1-3) vs 0, P = 0.043, respectively. Presence of drug information from
the pharmaceutical industry and education on prescribing for newly employed physicians was negatively
associated with adherence to the prescribing objectives: 1 (0-2) vs 3.5 (2.25-4.75), P = 0.005; 1 (0-2) vs 3 (1.5-4), P =
0.034, respectively.
Conclusion: Several characteristics of the primary health care units correlated with adherence to prescribing
objectives for rational drug use. Further research on this topic is needed and would constitute valuable information
for health care decision makers.
Background
The prescribing of drugs is an important issue for the
individual patient, since risks and benefits of the treat-
ment directly affect the patient. In Sweden, prescribed
drugs are reimbursed by the society. Hence, prescribing
o fd r u g si sa l s oak e yq u e s t i o nf r o map u b l i ce x p e n s e
perspective. Financing of drugs is a vast problem, since
costs for drugs are increasing and resources are limited
[1]. Evaluation of costs and benefits for alternative treat-
ment strategies is essential and rational drug use implies
physicians’ prescribing of drugs with favourable cost-
benefit balances.
Guidelines for recommended drugs are important for
rational drug use. However, prescribing and adherence
to prescribing guidelines vary between health care units
[2], for example according to patient characteristics
[3-5], physician characteristics [4], practice settings [4],
budgetary policies [6] and country of residence [7].
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In the region of Västra Götaland, Sweden, prescribing
objectives are set up for rational drug use. A national
sales register for prescribed drugs (Xplain) is used for
evaluation of the objectives. The register includes aggre-
gated data on age, sex, and residential area of the
patient, as well as information on the unit from which a
drug is prescribed, and the drug dispensed [e.g. number
of defined daily doses (DDD) and costs]. Each primary
health care unit is responsible for its own budget, which
shall cover its expenses for society reimbursements for
drugs.
The public primary health care of Göteborg in the
region of Västra Götaland, Sweden, consisted in 2007 of
25 units. The head of each primary health care unit
receives a monthly report on their results on the pre-
scribing objectives, as well as the overall results of all
units in Göteborg. Moreover, pharmacists present the
results to the physicians working in the unit at seminars
twice a year. Knowledge on factors correlated with
adherence to the prescribing objectives is essential for
rational use of drug.
The aim of the present study was to investigate corre-
lations between characteristics of primary health care
units and adherence to prescribing objectives for
rational drug use with focus on drug information from
the pharmaceutical industry.
Methods
A cross-sectional study was performed in all publicly run
primary health care units in Göteborg, Sweden (n = 25).
A questionnaire including questions on characteristics of
practice settings was sent in print by mail to the heads of
the primary health care units in November 2007. A letter
revealing the source of the questionnaire and assuring
anonymity of the units at presentation of results accom-
panied the questionnaire. Characteristics included in the
questionnaire were (i) size of the primary care unit (1 =
serving <5000 inhabitants, 2 = 5000-10000 inhabitants, 3
= 10000-15000 inhabitants, 4 = 15000-20000 inhabitants,
5 = >20000 inhabitants), (ii) profession of the head of the
unit, (iii) use of temporary physician from other employ-
ers, (iv) drug information from the pharmaceutical indus-
try, (v) producer-independent drug information, and (vi)
education on prescribing for newly employed physicians.
The questionnaire (in Swedish) can be obtained from the
corresponding author. Two weeks after sending the ques-
tionnaire, an e-mail reminder was sent to those who had
not responded.
For the primary health care units responding to the
questionnaire, a national register for sales of prescribed
drugs (Xplain) was used to extract prescribing data from
January-December 2007 concerning results on the six
regional prescribing objectives, including prescribing of
PPIs (proportion of generic omeprazol), ACEIs (propor-
tion ACEI of ACEIs and angiotensin receptor blockers
[ARBs]), statins (proportion of generic simvastatin), and
antidepressants (proportion selective serotonin reuptake
inhibitors [SSRI] of antidepressants, proportion non-
escitalopram of SSRIs and proportion generic mirtazapin
of mirtazapins). The regional primary health care autho-
rities arbitrarily defined appropriate adherence level to
the prescribing objectives. During 2007 these levels were
set at >80%, >70%, >80%, 75%, 95% and 98% of the pre-
scribed and dispensed DDD, respectively.
Statistics
Statistical analyses were conducted using SPSS 12.0.1.
Due to the small number of primary health care units in
the study, multivariate logistic regression could not be
performed. Spearman correlation coefficients were cal-
culated to evaluate bivariate correlations between ques-
tionnaire results and number of prescribing objectives
adhered to. Mann-Whitney’s test was used for compari-
son of results on the regional prescribing objectives in
primary health care units with or without drug informa-
tion from the pharmaceutical industry. Fisher’se x a c t
test was used for comparisons between categorical
values. A P-value < 0.05 was considered significant.
Values are presented as median (25
th-75
th percentile) if
not stated otherwise. Percentages are calculated with the
total number of responding units to the particular ques-
tion as denominator.
Results
Twenty-two out of 25 heads of primary health care units
responded to the questionnaire (response rate 88%),
though all questions were not responded upon. Charac-
teristics of the units according to the questionnaire are
presented in Table 1.
Bivariate correlations between characteristics of the
primary health care units and adherence to the prescrib-
ing objectives are presented in Table 2. A physician as
head and presence of producer-independent drug infor-
mation was positively correlated with adherence to the
prescribing objectives. Presence of drug information
from the pharmaceutical industry and education on pre-
scribing for newly employed physicians was negatively
correlated with adherence to the prescribing objectives.
Seventeen out of the 21 responding units (81%)
received drug information from the pharmaceutical
industry (one of which did not respond to the question
on profession of the head of unit). Presence of drug
information from the pharmaceutical industry was less
common with physician as head of the unit; six of ten
units headed by a physician had received information
from the pharmaceutical industry, whilst all ten units
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Presence of drug information from the pharmaceutical
industry was more common in units with education on
prescribing for newly employed physicians;15 out of 17
units receiving drug information from the pharmaceuti-
cal industry had education on prescribing for newly
employed physicians, whilst the corresponding number
for units without drug information from the pharmaceu-
tical industry was 1 out of 3 (P = 0.088). No other cor-
relations with P < 0.10 were found between
characteristics of the units revealed in the questionnaire.
Units with and without visits from the pharmaceutical
industry were geographically spread in the area.
Characteristics of the drug information from the phar-
maceutical industry are presented in Table 3. In 14 out
of 17 units (82%), representatives from other professions
than physicians also attended the information sessions.
In 8 units (47%), information was given more than once
a month.
The results on the six regional prescribing objectives
in primary health care units with or without drug infor-
mation from the pharmaceutical industry are presented
in Table 4. In 2007, the median number of DDD per
health care unit with and without drug information
from the pharmaceutical industry was for PPIs 88 836
(60 995-193 230) and 58 921 (40 097-72 843); for
ACEIs and ARBs 201 186 (159 657-319 914) and 139
755 (92 952-199 299); for statins 179 632 (144 807-248
018) and 143 463 (100 468-222 974); for antidepressants
185 875 (143 846-251 642) and 127 308 (75 052-179
393); for SSRIs 136 127 (107 924-172 396) and 95 649
(58 281-134 935); and for mirtazapins 26 346 (20 774-
31 695) and 12 469 (7 224-19 577).
Discussion
The results of the present study indicate that the profes-
sion of the head and the source of drug information
may be of importance for rational prescribing, as mea-
sured by adherence to prescribing objectives. Some of
these factors are correlated with each other, and a study
including more health care units would be of interest to
identify independent factors for adherence to prescribing
objectives. Therapeutic traditions at health care units
have previously been shown to influence prescribing [9].
The head of a health care unit has the responsibility
for the operational activity. Hence, this post is of utmost
Table 1 Characteristics of the primary health care units according to the questionnaire (n = 22).
Number of units (%) Number of not responding units
Physician as head of unit 10 (48) 1
Size of the unit (number of patients served) <5000 1 (5) 0
5000-10000 2 (9)
10000-15000 4 (18)
15000-20000 9 (41)
>20000 6 (27)
Temporary physicians 12 (55) 0
Drug information from the pharmaceutical industry 17 (81) 1
Producer-independent drug information 19 (86) 0
Education on prescribing for newly employed physicians 16 (76) 1
Values are presented as n (% of the responders).
Table 2 Correlation between number of prescribing objectives adhered to and factors investigated in the
questionnaire
Number of prescribing objectives adhered to median
(25
th-75
th percentile)
P-value
Yes No
Size of the unit NA NA 0.14
Physician as head of the unit 2.5 (1-3.25) 1 (0-2) 0.013
Temporary physicians 1 (0-2) 2 (1-3) 0.051
Drug information from the pharmaceutical industry 1 (0-2) 3.5 (2.25-4.75) 0.005
Producer-independent drug information 2 (1-3) 0 0.043
Education on prescribing for newly employed physicians 1 (0-2) 3 (1.5-4) 0.034
The total of six prescribing objectives concerned PPIs (proportion of generic omeprazol), ACEIs (proportion ACEI of ACEIs and angiotensin receptor blockers
[ARBs]), statins (proportion of generic simvastatin), and antidepressants (proportion selective serotonin reuptake inhibitors [SSRI] of antidepressants, proportion
non-escitalopram of SSRIs and proportion generic mirtazapin of mirtazapins). The arbitrarily defined appropriate adherence levels to the prescribing objectives
were set to 80%, 70%, 80%, 75%, 95% and 98% of the prescribed and dispensed DDDs, respectively.
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; DDD, defined daily dose; NA, not applicable; PPI, proton pump inhibitor; SSRI,
selective serotonin reuptake inhibitor
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edge the importance of this post for the prescribing of
drugs has not been investigated before.
Interestingly, for all health care units not receiving
drug information from the pharmaceutical industry, the
head of the unit was a physician. For the remaining
units, the head was a physician in only 6 of 16 cases
(38%). From our experience, representatives from the
pharmaceutical industry invite themselves for drug
information sessions rather than are invited by health
care representatives. Hence, it is up to the head to
decide whether to accept or reject the offer. The present
study does not allow conclusions concerning rationales
for the heads’ choice concerning this matter. However,
non-physician heads may have less knowledge on what
sort of information is provided. Their understanding of
the prescribing process may also be less prominent
since prescribing is not their area of expertise as they do
not prescribe themselves. The rationales for heads to
accept/reject drug information from the pharmaceutical
industry would be of interest to investigate further.
The majority of primary health care units received
drug information from the pharmaceutical industry, pre-
dominantly at lunchtime which is not included in work-
ing hours in Sweden. In many cases, representatives
from professions without prescribing authority, but who
work in close contact with patients, also receive the
information. Whether these groups of professionals may
influence patients’ requests of certain drugs is not
known.
In the present study, source of drug information was
correlated with prescribing. Primary health care units
not receiving drug information from the pharmaceutical
industry succeeded in adhering to the majority of the
prescribing objectives for rational drug use, whereas
those receiving information adhered to a far less extent.
Our results confirm the results of other studies, where
visits by pharmaceutical sales representatives were asso-
ciated with a broader range of drugs prescribed [10] and
increased prescribing costs [11,12].
Drug information is important for rational drug use,
which requires adequatek n o w l e d g eo nd r u g s ’ benefits,
risks and cost-effectiveness. The increasing volume of
information related to drugs and prescribing may make
it difficult for an individual primary care physician to
keep up to date with best practice. In 2007, all primary
health care units in Göteborg were offered producer-
independent drug information sessions from the Depart-
ment of Clinical Pharmacology. An important finding in
the present study is the correlation between producer-
Table 3 Characteristics of drug information from the pharmaceutical industry in units receiving this kind of
information (n = 17)
Number of primary health care units
n (%)
Frequency of visits Once a week 4 (24)
>Once a month 4 (24)
<Once a month 9 (53)
Attending professions Physicians only 3 (18)
Physicians and nurses 5 (29)
All personnel 9 (53)
Time of information Lunch ≥50% of occasions 13 (81)
Working hours ≤50% of occasions 14 (88)
Table 4 Results on the regional prescribing objectives in primary health care units with or without drug information
from the pharmaceutical industry.
Without drug information from the
pharmaceutical industry
(n = 4)
With drug information from the pharmaceutical
industry
(n = 17)
P-value*
Generic omeprazole of PPIs 77 (73-89) 77 (72-81) 0.59
ACEIs of ACEIs and ARBs 62 (52-72) 59 (54-61) 0.72
Generic simvastatin of statins 84 (81-92) 75 (71-80) 0.016
SSRI of antidepressants 77 (74-78) 71 (69-74) 0.020
Non-escitalopram of SSRIs 96 (94-97) 94 (91-96) 0.21
Generic mirtazapin of mirtazapins 84 (78-93) 85 (77-91) 0.86
Values are presented as median percentage (25
th-75
th percentile) of prescribed DDDs.
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; DDD, defined daily dose; PPI, proton pump inhibitor; SSRI, selective serotonin
reuptake inhibitor
*Mann Whitney’s test
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The majority of the health care units received this kind
of information and it would be of interest to learn more
about the rationales for the rejection of this offer. Pro-
ducer-independent drug information has previously
been shown favorable for rational prescribing [8].
A finding worth further attention is that education of
newly employed physicians on prescribing was nega-
tively correlated with rational drug use. This raises the
question on the quality of this education. Our results
also raise the question on the content and quality of
drug information from the pharmaceutical industry. Is it
possible to distinguish marketing and information from
a source dependent on sales of the products about
which they inform? The influence from the pharmaceu-
tical industry on prescribing is also of interest from
another point of view, since it is a distinct external
entity separate from the health care and therefore possi-
bly more easily controlled than factors ascending from
the health care itself, i.e. we can decide whether to
receive it or not.
A limitation of the present study is the small sample
size of 25 health care units, which makes multivariate
analyses inappropriate. Nevertheless, the study showed
several statistically significant findings, which would be
worthwhile to investigate further.
Conclusion
Profession of head and sources of drug information cor-
relate with adherence to prescribing objectives for
rational drug use. Further research on this topic is
needed and would constitute valuable information for
health care decision makers.
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